Loading...
NPI 1023438397 · Harwood Heights, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Simple Laboratories LLC is a clinical medical laboratory provider located in Harwood Heights, Illinois. This profile covers 117 Medicare and 227 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Simple Laboratories LLC |
| Address | 7444 W Wilson Ave Ste 111 |
| City | Harwood Heights |
| State | IL |
| ZIP | 60706 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 24, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $49.6M |
| Medicare | $4.3M |
SIMPLE LABORATORIES LLC’s billing profile is overwhelmingly concentrated in high-volume SARS‑CoV‑2 testing products: Medicare claims show U0003, 87635 and U0005 together account for a dominant share of lab activity, and the precomputed top‑3 Medicare codes account for 73.1% of this provider's total Medicare revenue. On Medicare U0003 (18.5K claims, $1.4M revenue) and 87635 (24.6K claims, $1.2M revenue) are individually large line items, and each is labeled an "extreme outlier" versus national peers, signaling a specialized, high‑throughput COVID testing operation rather than a general ambulatory draw site.
The provider’s Medicaid business is materially larger than its Medicare business: reported Medicaid revenue is $49.6M versus Medicare revenue of $4.3M, indicating Medicaid is the primary payer by scale. Within Medicaid, U0003 alone represents $19.5M (44.2% of Medicaid revenue), and the precomputed top‑3 Medicaid codes account for 65.3% of this provider's total Medicaid revenue, which underscores the same COVID testing concentration on the state payer side.
Competitive standing by payer is asymmetric but decisive: for several top codes the provider ranks at or near the top of peer lists, reflecting market leadership. On Medicare, 87635 ranks #2 of 9976 providers nationally (100th percentile; extreme outlier) and U0003 ranks #13 of 973 (99th percentile; extreme outlier), while in‑state Medicaid ranks show U0003 at #2 of 350 (100th percentile; extreme outlier) and G0480 at #2 of 71 (99th percentile; notably above typical state volume), all consistent with a major statewide player for COVID testing and toxicology.
Service‑line mix indicates a dual focus on high‑throughput molecular infectious disease testing and toxicology: top codes across both payers are U0003, U0005 and 87635 (SARS‑CoV‑2 nucleic acid testing and rapid/high‑throughput variants) alongside large G0480/G0481 and 80307 activity (definitive and presumptive drug testing). Medicaid detail shows very large volumes for G0480 (139.7K claims, $5.4M revenue) and for presumptive/definitive toxicology codes such as 80307 (59.9K claims, $2.5M revenue) and 80361 (24.3K claims, $243.2K revenue), supporting an operational model that pairs mass infectious testing with high‑volume toxicology services.
Specimen collection and on‑site collection support are also notable components of operations: G2024 appears with high counts on both payers (Medicare 14.7K claims, $367.2K revenue; Medicaid 94.4K claims, $1.8M revenue) and ranks highly versus peers, indicating the lab provides large‑scale specimen collection for SNF/HHA and similar channels in addition to central lab testing. This pattern is consistent with an integrated workflow that handles outreach collection as well as centralized analysis.
While COVID and toxicology codes dominate revenue, the provider also reports substantial volumes of routine clinical chemistry and immunology panels (for example, 84443 TSH, 80053 CMP, 82306 vitamin D and 85025 CBC) across both payers. Many of these routine tests appear at high percentile ranks (often 97th–99th) but are described as "typical, unremarkable volume" in the data, implying that beyond the pandemic and toxicology activity the lab maintains a broad baseline clinical testing footprint typical of a full‑service clinical lab.
The provider’s NPI tenure—enumerated 2014-04-24 (~12 years ago)—indicates an established operation with multi‑year presence in the market. That longevity, combined with extreme outlier rankings on core high‑revenue codes, suggests the organization scaled (or pivoted) successfully into high‑volume molecular and toxicology testing over time rather than being a newly formed surge actor.
Not all high‑percentile code appearances indicate extraordinary behavior across the board: several commonly ordered tests (for example 84443, 80053, 82306) rank at high national/state percentiles but are noted as "typical, unremarkable volume" in their descriptors, which suggests the provider’s exceptional standing is concentrated in a subset of service lines (primarily SARS‑CoV‑2 testing and selected toxicology codes) rather than across every lab modality. Analysts should treat the molecular/toxicology concentrations as the primary driver of competitive position while recognizing a normal baseline of routine lab services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
117 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 18,540 | $70 | $1.4M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 24,590 | $50 | $1.2M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 17,750 | $30 | $443.8K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 14,690 | $30 | $367.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 920 | $150 | $140.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 900 | $110 | $99.3K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 2,880 | $30 | $83.4K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 4,230 | $20 | $67.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 4,680 | $10 | $60.9K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 5,920 | $10 | $59.2K |
Showing 1–10 of 117
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
117 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| U0003 | 5 | 100 | 230 | $70 | $249.1K |
| P9603 | 32 | 40 | 35,960 | $1 | $232.2K |
| G2024 | 2 | 10 | 2,550 | $20 | $195.3K |
| 87798 | 48 | 70 | 750 | $30 | $172.3K |
| G0471 | 5 | 10 | 940 | $10 | $166.2K |
| G0480 | 3 | 20 | 50 | $110 | $89.9K |
| U0005 | 5 | 100 | 270 | $20 | $86.3K |
| 87481 | 48 | 60 | 120 | $30 | $47.3K |
| 87088 | 9 | 30 | 140 | $10 | $31.9K |
| 80307 | 9 | 70 | 120 | $60 | $27.2K |
Showing 1–10 of 117
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
227 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 319,870 | $60 | $19.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 139,740 | $40 | $5.4M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 215,060 | $20 | $3.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 59,920 | $40 | $2.5M |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 94,400 | $20 | $1.8M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9,680 | $120 | $1.1M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 28,990 | $40 | $1.1M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 17,740 | $50 | $940.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 21,880 | $40 | $809.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 21,770 | $40 | $805.3K |
Showing 1–10 of 227
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
227 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 6 | 10 | 210 | $70 | $1.4M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16 | 20 | 940 | $110 | $1.1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 70 | 570 | $50 | $565.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2 | 350 | 400 | $70 | $514.7K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 2 | 20 | 470 | $20 | $351.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 30 | 420 | $70 | $308.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 10 | 2,430 | $70 | $286.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4 | 280 | 1,120 | $30 | $218.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2 | 210 | 680 | $20 | $206.4K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 43 | 170 | 150 | $200 | $190.9K |
Showing 1–10 of 227
Other providers in the same ZIP code as Simple Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Norwood Park Fire Protection District | IL | Land Ambulance | $293.6K | $4M |
| Labpro Inc | IL | Clinical Medical Laboratory | $0 | $3.2M |
| Amish Patel | IL | Physical Medicine & Rehabilitation Physician | $696.4K | $156.1K |
| Lisa Vasquez | IL | Psychiatric/Mental Health Nurse Practitioner | $77.9K | $141K |
| Helena Podgorska | IL | Family Medicine Physician | $34.7K | $87.2K |
| Lori Risner | IL | Occupational Therapist | $40.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.